These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594 [TBL] [Abstract][Full Text] [Related]
6. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system. Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431 [TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Lindholm A; Bixo M; Eliasson M; Hudecova M; Arnadottir R; Holte J; Poromaa IS Gynecol Endocrinol; 2010 Oct; 26(10):743-8. PubMed ID: 20500107 [TBL] [Abstract][Full Text] [Related]
8. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. Mannerås-Holm L; Baghaei F; Holm G; Janson PO; Ohlsson C; Lönn M; Stener-Victorin E J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248 [TBL] [Abstract][Full Text] [Related]
9. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome. Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272 [TBL] [Abstract][Full Text] [Related]
11. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Nehir Aytan A; Bastu E; Demiral I; Bulut H; Dogan M; Buyru F Gynecol Endocrinol; 2016 Sep; 32(9):709-713. PubMed ID: 26951881 [TBL] [Abstract][Full Text] [Related]
12. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Gonzalez F; Thusu K; Abdel-Rahman E; Prabhala A; Tomani M; Dandona P Metabolism; 1999 Apr; 48(4):437-41. PubMed ID: 10206434 [TBL] [Abstract][Full Text] [Related]
13. High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome. Chen MJ; Chen CD; Yang JH; Chen CL; Ho HN; Yang WS; Yang YS Hum Reprod; 2011 Jan; 26(1):227-34. PubMed ID: 21088016 [TBL] [Abstract][Full Text] [Related]
14. Assessment of PON1 activity and circulating TF levels in relation to BMI, testosterone, HOMA-IR, HDL-C, LDL-C, CHO, SOD activity and TAC in women with PCOS: An observational study. Jeelani H; Ganie MA; Masood A; Amin S; Kawa IA; Fatima Q; Manzoor S; Parvez T; Naikoo NA; Rashid F Diabetes Metab Syndr; 2019; 13(5):2907-2915. PubMed ID: 31425955 [TBL] [Abstract][Full Text] [Related]
15. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. Durmus U; Duran C; Ecirli S J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846 [TBL] [Abstract][Full Text] [Related]
16. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. Faloia E; Canibus P; Gatti C; Frezza F; Santangelo M; Garrapa GG; Boscaro M J Endocrinol Invest; 2004 May; 27(5):424-9. PubMed ID: 15279073 [TBL] [Abstract][Full Text] [Related]
17. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome. González F; Rote NS; Minium J; Kirwan JP J Endocrinol; 2006 Mar; 188(3):521-9. PubMed ID: 16522732 [TBL] [Abstract][Full Text] [Related]
18. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Demi R İ; Guler A; Alarslan P; Isil AM; Ucman O; Aslanipour B; Calan M Endocrine; 2019 Jul; 65(1):175-183. PubMed ID: 31154608 [TBL] [Abstract][Full Text] [Related]